尿毒清颗粒联合复方α-酮酸对腹膜透析患者残余肾功能保护的研究

To study the role of Niaoduqing granules combined with compoundα-ketoacid tablets in protecting the residual renal function of peritoneal dialysis patients

目的探讨尿毒清颗粒联合复方α-酮酸对腹膜透析(PD)患者残余肾功能的保护。方法选取63例终末期肾脏病PD患者随机分为单纯PD组(A组)、尿毒清颗粒联合PD治疗组(B组)、尿毒清颗粒联合复方α酮酸配合PD治疗组(C组),每组各21例。随访半年观察三组尿素清除指数(Kt/V)、血肌酐(Scr)、内生肌酐清除率(Ccr)等指标。结果 B组及C组Kt/V、Ccr均高于A组,同时B组及C组Scr值均低于A组,(P<0.05),而C组改善更加明显,优于B组(P<0.05)。结论与单纯PD对残余肾功能的保护相比,尿毒清颗粒联合复方α-酮酸配合PD更能有效地保护PD患者的残余肾功能,延缓肾功能的恶化,改善尿毒症症状。

Objective To discuss the role of Niaoduqing granules combined with compoundα-ketoacid tablets in protecting the residual renal function of peritoneal dialysis patients. Methods Sixty-three patients with end-stage peritoneal dialysis disease were selected and randomly divided into three groups, 21 cases in each group. Group A only recived peritoneal dialysis;Group B received the treatment of Niaoduqing granules combined with peritoneal dialysis and Group C received the treatment of Niaoduqing granules combined with compoundα-ketoacid tablets and peritoneal dialysis. After half a year following-up, the urea clearance index(Kt/V), serum creatinine(Scr) and endogenous creatinine clearance rate(Ccr) of the three groups were observed. Results The levels of Kt/V and Ccr in group B and group C were both higher than those of group A, while the serum creatinine(Scr) of group B and group C were lower than that of group A. The differences above were statistically significant(P<0.05). The levels of group C were obviously better than those of group B(P<0.05). Conclusion Niaoduqing granules combined with compoundα-ketoacid tablets and peritoneal dialysis can effectively protect the residual renal function of peritoneal dialysis patients, which can delay the development of renal failure and ease the symptoms of uremia.